The original rationale behind BZ development and use in multiple myeloma was the inhibition of NFκB-dependent transcription of anti-apoptotic genes, by blocking the inducible proteasomal degradation of IκBα and nuclear translocation of NFκB subunits [21, 22]. Here, NFKB1 is linked to plasma cell myeloma.